03 / RESEARCH PEPTIDE FUNDAMENTALS — LEAD ENTRY
Semaglutide: The Deepest Trial Record On This Desk
An FDA-approved GLP-1 receptor agonist backed by some of the largest randomized trials ever run on a metabolic drug — and, because millions take it, one of the largest bodies of user-reported experience covered on this site.
The short version
Semaglutide is a GLP-1 receptor agonist — a synthetic peptide engineered to mimic and outlast a natural gut hormone called GLP-1, which signals fullness and helps regulate blood sugar after eating. It is FDA-approved for type 2 diabetes, chronic weight management, reducing cardiovascular events in adults with existing cardiovascular disease, and (since 2025) a form of fatty liver disease. It comes as a once-weekly injection or a once-daily oral tablet.
This is the compound on this desk with by far the deepest published record: multiple trials with thousands of participants each, running for well over a year in some cases [11][12][13][14]. It also lost the head-to-head weight-loss comparison to tirzepatide, a dual-receptor peptide covered elsewhere on this site — tirzepatide produced roughly 6.5 percentage points more weight loss over 72 weeks in the one trial that compared them directly [11]. This page reports what was studied, in the populations it was studied in; it lists no dose as a recommendation and gives no medical advice.
What it is
Semaglutide is a 31-amino-acid synthetic peptide built on the backbone of human GLP-1, sharing roughly 94% of its sequence with the natural hormone. Two changes give it staying power: at position 8, a substitution blocks the main enzyme that normally destroys GLP-1 within minutes, and at position 34 a second substitution adds further stability. A fatty side chain attached elsewhere on the molecule causes it to bind tightly and reversibly to albumin, the most abundant protein in blood plasma — which shields it from being filtered out by the kidneys and gives it a circulating half-life of roughly a week, the structural basis for once-weekly dosing. The oral tablet uses a separate absorption-enhancing ingredient to get a small amount of the peptide across the stomach lining before digestive enzymes break it down, and must be taken strictly fasted for that reason.
How it works
Semaglutide activates GLP-1 receptors throughout the body. In the pancreas, it boosts insulin release only when blood sugar is already elevated and suppresses glucagon, the hormone that raises blood sugar — a glucose-dependent mechanism that keeps the risk of dangerously low blood sugar low when it is used alone. It slows how quickly the stomach empties, which blunts blood-sugar spikes after meals and contributes to nausea as a side effect.
Its weight effect is mostly a brain effect. Semaglutide reaches appetite-control circuits in the hypothalamus and brainstem — particularly a region called the arcuate nucleus and another called the area postrema — where it activates neurons that signal fullness and quiets neurons that drive hunger. In rodent studies, this central action reduced food intake and changed food preference without lowering how much energy the animals burned [16], which is the mechanistic basis for why patients describe reduced appetite rather than simply feeling too sick to eat.
What the research shows
Head-to-head against tirzepatide. A 72-week open-label trial of 751 adults with obesity directly compared the top tolerated dose of tirzepatide against the top tolerated dose of semaglutide. Tirzepatide produced 20.2% mean weight loss versus 13.7% for semaglutide, a statistically significant difference (P<0.001) [11]. This is the most direct evidence available comparing the two, and it places semaglutide as the benchmark the newer dual-receptor peptide surpassed.
Weight management (STEP 1). In 1,961 adults with overweight or obesity and no diabetes, once-weekly semaglutide produced 14.9% mean body-weight loss at 68 weeks versus 2.4% with placebo — a roughly 12.4 percentage-point difference [14].
Cardiovascular outcomes (SELECT). In 17,604 adults with existing cardiovascular disease and overweight or obesity but no diabetes, semaglutide reduced the combined rate of cardiovascular death, heart attack, or stroke by 20% relative to placebo (hazard ratio 0.80; P<0.001) [13].
Kidney outcomes (FLOW). In 3,533 adults with type 2 diabetes and chronic kidney disease, semaglutide reduced a composite of kidney failure, major kidney-function decline, or kidney- or cardiovascular-related death by 24% relative to placebo [12].
Cardiovascular outcomes and a safety signal (SUSTAIN-6). In 3,297 adults with type 2 diabetes at elevated cardiovascular risk, semaglutide reduced the same cardiovascular composite by 26% relative to placebo — but complications of diabetic eye disease (retinopathy) were significantly more frequent with semaglutide, concentrated in people who already had retinopathy and were undergoing rapid blood-sugar correction [17].
Safety profile. A dedicated safety review characterizes semaglutide's overall risk-benefit balance as favorable in type 2 diabetes, dominated by mild-to-moderate gastrointestinal effects (nausea in roughly a third of patients), with an increased risk of gallbladder disease and pancreatic- and thyroid-cancer signals that remain unconfirmed due to how rarely they occur [15].
Reported effects, cautions & safety
What follows is anecdotal, not clinical evidence — reports from patient and research-use communities, not measurements from a trial, and none of it names a dose.
Reported benefits (anecdotal, not clinical evidence): By far the most common thing people describe is the background mental chatter about food going quiet — often called "food noise" — usually within the first week or two. People report eating a third to half of their previous portions, losing interest in sugar and fried or greasy food, and steady weight loss over months. People being treated for type 2 diabetes commonly report markedly improved blood-sugar readings, and a widely discussed secondary effect is reduced interest in drinking alcohol.
Reported adverse effects (anecdotal, not clinical evidence): Nausea is the dominant complaint, mentioned by roughly a third of reviewers, usually peaking in the first weeks and after each dose increase. A distinctive complaint is sulfur-smelling burps, often accompanied by bloating. Bowel changes — constipation, diarrhea, or both in alternation — are common, alongside acid reflux, early fatigue on injection day, and occasional headaches often tied to not drinking enough water. Some people describe food aversions or a heightened, unpleasant sensitivity to smells. A subset report hair shedding after several months, generally attributed to the pace of weight loss rather than to the drug itself, and mild injection-site reactions are sometimes noted.
Cited cautions: Gastrointestinal intolerance during dose escalation is the leading clinical adverse effect and the main reason people stop treatment [15]. The label carries a boxed warning about thyroid C-cell tumors based on rodent data; a personal or family history of medullary thyroid carcinoma or MEN-2 is a contraindication, though the human risk is not established [15]. Acute pancreatitis is a monitored class warning without a confirmed elevated risk in the literature [15]. An increased risk of gallbladder and biliary disease is a real, if modest, finding attributed largely to the pace of weight loss itself [15]. And diabetic retinopathy complications were significantly more frequent in one large trial among people with pre-existing retinopathy who lowered their blood sugar quickly [15][17]. Beyond these cited findings, a few further cautions are well recognized in the literature without a specific figure to cite here: a portion of weight lost includes lean muscle mass rather than fat alone; stopping treatment is commonly followed by substantial weight regain, framing this as a chronic rather than curative therapy; semaglutide is contraindicated in pregnancy; and the oral tablet must be taken on an empty stomach, apart from food, drink, or other medication, or its already-low absorption drops further.
Where it fits in Research Peptide Fundamentals
Semaglutide anchors the deep-evidence, deep-anecdote corner of this desk. It is the compound with the largest, most rigorous published trial record here [11][12][13][14][17] and also the one with the largest volume of genuine patient-community reporting, simply because it has been an approved medicine taken by millions of people for years. That combination — real numbers and real volume of lived experience, kept clearly separated — is the model this whole site is built around. Tirzepatide is the newer peptide that beat it in direct comparison [11]; GHK-Cu and KPV sit much further down the evidence curve. See the comparison page for the full picture across all four.
